Mehra MR - Search Results

1

Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial.

Lindenfeld J, Zile MR, Desai AS, Bhatt K, Ducharme A, Horstmanshof D, Krim SR, Maisel A, Mehra MR, Paul S, Sears SF, Sauer AJ, Smart F, Zughaib M, Castaneda P, Kelly J, Johnson N, Sood P, Ginn G, Henderson J, Adamson PB, Costanzo MR. Lindenfeld J, et al. Among authors: mehra mr. Lancet. 2021 Sep 11;398(10304):991-1001. doi: 10.1016/S0140-6736(21)01754-2. Epub 2021 Aug 27. Lancet. 2021. PMID: 34461042 Clinical Trial.

2

Presence of severe intimal thickening by intravascular ultrasonography predicts cardiac events in cardiac allograft vasculopathy.

Mehra MR, Ventura HO, Stapleton DD, Smart FW, Collins TC, Ramee SR. Mehra MR, et al. J Heart Lung Transplant. 1995 Jul-Aug;14(4):632-9. J Heart Lung Transplant. 1995. PMID: 7578168

3

Predictive model to assess risk for cardiac allograft vasculopathy: an intravascular ultrasound study.

Mehra MR, Ventura HO, Chambers R, Collins TJ, Ramee SR, Kates MA, Smart FW, Stapleton DD. Mehra MR, et al. J Am Coll Cardiol. 1995 Nov 15;26(6):1537-44. doi: 10.1016/0735-1097(95)00357-6. J Am Coll Cardiol. 1995. PMID: 7594082 Free article.

4

New developments in the diagnosis and management of cardiac allograft vasculopathy.

Mehra MR, Ventura HO, Smart FW, Stapleton DD, Collins TJ, Ramee SR, Murgo JP, White CJ. Mehra MR, et al. Tex Heart Inst J. 1995;22(2):138-44. Tex Heart Inst J. 1995. PMID: 7647597 Free PMC article. Review.

5

Vibrio vulnificus sepsis in solid organ transplantation: a medical nemesis.

Ali A, Mehra MR, Stapleton DD, Kemmerly SA, Ramireddy K, Smart FW, Augustine S, Ventura HO. Ali A, et al. Among authors: mehra mr. J Heart Lung Transplant. 1995 May-Jun;14(3):598-600. J Heart Lung Transplant. 1995. PMID: 7654744

6

An intravascular ultrasound study of the influence of angiotensin-converting enzyme inhibitors and calcium entry blockers on the development of cardiac allograft vasculopathy.

Mehra MR, Ventura HO, Smart FW, Collins TJ, Ramee SR, Stapleton DD. Mehra MR, et al. Am J Cardiol. 1995 Apr 15;75(12):853-4. doi: 10.1016/s0002-9149(99)80432-9. Am J Cardiol. 1995. PMID: 7717300 No abstract available.

7

Does donor and recipient sex influence the development of cardiac allograft vasculopathy?

Mehra MR, Ventura HO, Escobar A, Cassidy CA, Smart FW, Stapleton DD. Mehra MR, et al. Transplant Proc. 1995 Jun;27(3):1926-9. Transplant Proc. 1995. PMID: 7792839 No abstract available.

8

Cardiac allograft vasculopathy: current concepts.

Ventura HO, Mehra MR, Smart FW, Stapleton DD. Ventura HO, et al. Among authors: mehra mr. Am Heart J. 1995 Apr;129(4):791-9. doi: 10.1016/0002-8703(95)90331-3. Am Heart J. 1995. PMID: 7900633 Review.

9

Cardiac allograft vasculopathy assessed by intravascular ultrasonography and nonimmunologic risk factors.

Escobar A, Ventura HO, Stapleton DD, Mehra MR, Ramee SR, Collins TJ, Jain SP, Smart FW, White CJ. Escobar A, et al. Among authors: mehra mr. Am J Cardiol. 1994 Nov 15;74(10):1042-6. doi: 10.1016/0002-9149(94)90856-7. Am J Cardiol. 1994. PMID: 7977044

10

The prognostic significance of intimal proliferation in cardiac allograft vasculopathy: a paradigm shift.

Mehra MR, Ventura HO, Stapleton DD, Smart FW. Mehra MR, et al. J Heart Lung Transplant. 1995 Nov-Dec;14(6 Pt 2):S207-11. J Heart Lung Transplant. 1995. PMID: 8719487 Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

556 results

Search Page